Pharmacological specificity of Δ9-tetrahydrocannabinol discrimination in rats

[1]  A. Hiltunen,et al.  Limited stimulus generalization between △9-THC and diazepam in pigeons and gerbils , 2004, Psychopharmacology.

[2]  R. L. Barrett,et al.  Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats , 1995, Neuropharmacology.

[3]  M W Fischman,et al.  Performance-based testing for drugs of abuse: dose and time profiles of marijuana, amphetamine, alcohol, and diazepam. , 1993, Journal of analytical toxicology.

[4]  R. L. Barrett,et al.  Discriminative stimulus effects of Δ 9-tetrahydrocannabinol and Δ 9–11-tetrahydrocannabinol in rats and rhesus monkeys , 1993, Neuropharmacology.

[5]  R. L. Barrett,et al.  Discriminative stimulus effects of delta 9-tetrahydrocannabinol and delta 9-11-tetrahydrocannabinol in rats and rhesus monkeys. , 1993, Neuropharmacology.

[6]  L. Gold,et al.  Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. , 1992, The Journal of pharmacology and experimental therapeutics.

[7]  R. L. Barrett,et al.  A comparison of the discriminative stimulus properties of delta 9-tetrahydrocannabinol and CP 55,940 in rats and rhesus monkeys. , 1992, The Journal of pharmacology and experimental therapeutics.

[8]  W. R. Prescott,et al.  Δ9-Tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication , 1992, Neuroscience & Biobehavioral Reviews.

[9]  I. Yamamoto,et al.  Cannabinoid metabolite interacts with benzodiazepine receptor , 1992 .

[10]  R. Pertwee,et al.  Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids , 1991, Neuropharmacology.

[11]  R. Pertwee,et al.  Drugs which stimulate or facilitate central cholinergic transmission interact synergistically with delta-9-tetrahydrocannabinol to produce marked catalepsy in mice , 1991, Neuropharmacology.

[12]  M. Green,et al.  Pharmacological characterization of cannabinoids in the elevated plus maze. , 1990, The Journal of pharmacology and experimental therapeutics.

[13]  L. Hollister,et al.  The benzodiazepine receptor antagonist, flumazenil does not block clinical effects of delta-9-tetrahydrocannabinol. , 1990, Life sciences.

[14]  S. Greentree,et al.  Drugs which stimulate or facilitate central GABAergic transmission interact synergistically with delta-9-tetrahydrocannabinol to produce marked catalepsy in mice , 1988, Neuropharmacology.

[15]  S. Greentree,et al.  Delta-9-tetrahydrocannabinol-induced catalepsy in mice is enhanced by pretreatment with flurazepam or chlordiazepoxide , 1988, Neuropharmacology.

[16]  R. Pertwee.  The central neuropharmacology of psychotropic cannabinoids. , 1988, Pharmacology & therapeutics.

[17]  A. Jakubovic,et al.  Interaction of a water-soluble derivative of delta-9-tetrahydrocannabinol with [3H]diazepam and [3H]flunitrazepam binding to rat brain membranes , 1987, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[18]  A. Hiltunen,et al.  Cannabimimetic activity of cannabinol in rats and pigeons , 1987, Neuropharmacology.

[19]  S. Oja,et al.  Effects of the anticonvulsant taurine derivative, taltrimide, on membrane transport and binding of GABA and taurine in the mouse cerebrum , 1987, Neuropharmacology.

[20]  L. Harris,et al.  The role of benzodiazepine receptors in the discriminative stimulus properties of delta-9-tetrahydrocannabinol. , 1986, Life sciences.

[21]  J. Trivedi,et al.  Antianxiety effect of cannabis: Involvement of central benzodiazepine receptors , 1986, Biological Psychiatry.

[22]  A. Weissman,et al.  Discriminative Stimulus Properties of Δ9‐Tetrahydrocannabinol: Mechanistic Studies , 1981 .

[23]  D. McMillan,et al.  Discriminative stimulus properties of tetrahydrocannabinols and related drugs in rats and pigeons , 1979, Neuropharmacology.